YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Bill Gates Pulls Out of India’s AI Impact Summit Amid Controversy and Event Mismanagement 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
